We propose continuation of a multidisciplinary research training program in neuro-oncology based at the Massachusetts General Hospital. The primary objective of this two year program is to train physician- scientists capable of providing a critical bridge between the biological sciences and experimental therapeutics. In order to achieve this objective the training program emphasizes a didactic curriculum in clinical research methodology as well as mentor-supervised laboratory and clinical research experience. All clinical and laboratory mentors participating in this training program have extensive experience in neuro- oncology research and training and provide an excellent resource for trainees interested in translational research. All trainees have access to senior biostatistical and computing support on all projects. An advisory committee headed by the program director oversees the training program. In addition to clinical and basic science research facilities at the Massachusetts General Hospital, the Brigham and Women's Hospital, the Dana-Farber Cancer Institute and Harvard Medical School the program has expanded to include investigators at the Children's Hospital, the Harvard School of Public Health and the Scheppens Eye Research Institute. There is no overlap between our unique grant focused on nervous system tumors and existing K12 and T32 grants at Harvard focused on adult medical oncology. Candidates include physicians completing clinical training in adult and pediatric neuromedical oncology, adult and pediatric neurosurgical oncology, adult and pediatric medical oncology and radiation oncology. A qualified pool of applicants from these disciplines can be expected to grow from existing and developing sources. Each trainee has a dedicated two-year block for research and training with minimal clinical responsibilities. Four postdoctoral positions are requested per year for five years with each trainee making a two year commitment to investigation. Applicants will be selected through active recruitment by the program and individual faculty. We believe that the proposed training program capitalizes on an existing group of outstanding mentors and superb training facilities and will have the capability to produce productive clinician scientists in neuro- oncology. Since the original award in 2002 the program has accepted trainees from 4 oncology disciplines ncluding adult neuromedical oncology, adult neurosurgical oncology, pediatric neuro-surgical oncology and radiation oncology. Each trainee has been assigned a multi-disciplinary mentoring committee to provide guidance and career advice. Graduates from the first cycle of the award have accepted faculty positions and are applying for NIH-based individual research grants. In addition, over the course of the last funding cycle the program has been considerably strengthened by expansion and diversification of the advisory committee, faculty, trainee and resource base.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Physician Scientist Award (Program) (PSA) (K12)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RTRB-L (J1))
Program Officer
Lei, Ming
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Hess, Clayton B; Indelicato, Daniel J; Paulino, Arnold C et al. (2018) An Update From the Pediatric Proton Consortium Registry. Front Oncol 8:165
Andronesi, Ovidiu C; Arrillaga-Romany, Isabel C; Ly, K Ina et al. (2018) Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nat Commun 9:1474
Miller, Julie J; Wick, Wolfgang (2018) What's New in Grade II and Grade III Gliomas? Semin Neurol 38:41-49
Wang, Nancy; Bertalan, Mia S; Brastianos, Priscilla K (2018) Leptomeningeal metastasis from systemic cancer: Review and update on management. Cancer 124:21-35
Filbin, Mariella G; Tirosh, Itay; Hovestadt, Volker et al. (2018) Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science 360:331-335
Wang, Nancy; Osswald, Matthias (2018) Meningiomas: Overview and New Directions in Therapy. Semin Neurol 38:112-120
Venteicher, Andrew S; Tirosh, Itay; Hebert, Christine et al. (2017) Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science 355:
Tateishi, Kensuke; Higuchi, Fumi; Miller, Julie J et al. (2017) The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity. Cancer Res 77:4102-4115
Brastianos, Priscilla K; Santagata, Sandro (2016) ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma. Eur J Endocrinol 174:R139-44
Ohnishi, Takashi; Nakamura, Yuka; Tanaka, Toru et al. (2016) Deformable image registration between pathological images and MR image via an optical macro image. Pathol Res Pract 212:927-936

Showing the most recent 10 out of 45 publications